FEDERAL LOBBYING RECORDS
LOBBYING FILINGS AND MARKET CONTEXT
Indexed federal lobbying filings mapped to clients, registrants, and public-company tickers. Transaction dates are compared with filing periods to identify date-proximity review flags. Proximity does not establish coordination, influence, or wrongdoing.
Filings tracked
20,641
thru 2026-07-15
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,260
paying companies
Tickers targeted
1,219
public companies
Clients by reported amount
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 48 | $46.9M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 13 | $45.0M |
| 4 | VISA INC.V | 46 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 37 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 76 | $29.1M |
| 7 |  FEDEX CORPORATIONFDXW | 71 | $27.9M |
| 8 |  ELI LILLY AND COMPANYLLY | 60 | $27.4M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 147 | $25.3M |
| 10 |  COMCAST CORPORATIONCMCSV | 183 | $24.9M |
| 11 |  AMGEN INCAMGN | 19 | $24.9M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 54 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 83 | $22.8M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 131 | $21.3M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 41 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 32 | $19.8M |
| 20 |  MICROSOFT CORPORATIONMSFT | 107 | $18.9M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  BOEING COMPANYBA | 24 | $17.0M |
| 23 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 60 | $16.8M |
Mapped tickers by reported amount
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 134 | $50.3M |
| 2 | PFE Pfizer Inc. | 89 | $48.7M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 47 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 82 | $35.4M |
| 6 | LMT Lockheed Martin Corporation | 92 | $29.5M |
| 7 | FDX FedEx Corporation | 83 | $28.4M |
| 8 | LLY Eli Lilly and Company | 88 | $28.4M |
| 9 | AMGN Amgen Inc. | 100 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 66 | $27.0M |
| 12 | GOOGL Alphabet Inc. Class A | 128 | $26.8M |
| 13 | MO | 172 | $26.4M |
| 14 | SO Southern Company | 110 | $26.2M |
| 15 | UNH UnitedHealth Group Inc. | 68 | $24.0M |
| 16 | VZ Verizon Communications Inc. | 119 | $23.8M |
| 17 | TMUS | 170 | $22.9M |
| 18 |  CHTR | 142 | $22.8M |
| 19 | GD General Dynamics Corporation | 131 | $22.6M |
| 20 |  TAT&T Inc. | 137 | $21.7M |
| 21 | ORCL Oracle Corporation | 135 | $20.8M |
| 22 | CMCSA Comcast Corporation | 142 | $20.5M |
| 23 | OXY Occidental Petroleum Corporation | 38 | $20.1M |
| 24 | CI The Cigna Group | 64 | $19.9M |
| 25 | MSFT Microsoft Corporation | 126 | $19.3M |
🆕 Filtered Filings · GILEAD SCIENCES INC
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $3.2M | Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying the Inflation Reduction Act and other drug pricing |
| 2026-01-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying |
| 2025-10-20 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $2.8M | Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying |
| 2025-07-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate for provisions modifying |
| 2025-04-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $1.7M | International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. A |
| 2025-01-21 | GILD | GILEAD SCIENCES INC | GILEAD SCIENCES, INC. | $2.4M | International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. A |